ANDA 202585, held by Rising Pharmaceuticals. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 202585 (Dexmedetomidine Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Nov 24, 2014, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 24, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| Jun 19, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 24, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters